Scope and Purpose
This guideline covers the diagnosis, risk stratification, and management of chronic lymphocytic leukaemia (CLL) in adults aged ≥18 years. It integrates recommendations from three major international societies — ELN (via ESMO 2024), BSH (2025 update), and ASH/NCCN (2024) — with explicit identification of which recommendations are applicable to UK clinical practice under NICE commissioning.
The guideline applies to primary and relapsed/refractory CLL in outpatient haematology, day unit, and inpatient settings. Small lymphocytic lymphoma (SLL) shares the same biological entity and management principles. Prolymphocytic leukaemia and Richter's transformation are addressed under special populations.
The following NICE-commissioned regimens define UK clinical practice for CLL. Treatment outside these pathways requires individual funding approval or enrolment in a clinical trial:
- TA429 — Ibrutinib for previously untreated CLL with del(17p) or TP53 mutation (where CIT is unsuitable), and for previously treated CLL (de-prioritised for new starts — BSH 2025)
- TA1119 — Venetoclax + obinutuzumab (fixed 12 cycles) for untreated CLL
- TA689 — Acalabrutinib monotherapy for untreated CLL with del(17p)/TP53 or where ibrutinib unsuitable; and for previously treated CLL (NICE TA689 did not appraise the obinutuzumab combination)
- TA891 — Ibrutinib + venetoclax (fixed-duration, first-line)
- TA796 — Venetoclax monotherapy for R/R CLL (post-BTKi or post-CIT)
- TA561 — Venetoclax + rituximab for R/R CLL (previously treated)
Always verify current NICE guidance — TA numbers and commissioning criteria are subject to revision.
Clinical Overview and Epidemiology
CLL is a chronic, treatable B-cell malignancy with a highly variable disease course. Long remissions are common with modern targeted agents, and some patients achieve undetectable MRD. However, disease control rather than cure is the current aim of standard therapy outside clinical trials. CLL should not be described as simply "incurable" — the nuanced truth is that some patients never require treatment, many achieve excellent and prolonged responses, and allogeneic transplantation or experimental approaches offer potential cure for a selected minority. For many patients, CLL behaves as a chronic disease compatible with prolonged survival, often with extended treatment-free periods or durable responses to therapy. However, outcomes are heterogeneous — a minority experience aggressive disease, Richter's transformation, or serious treatment-related complications.
CLL is the most common leukaemia in the Western world, with an incidence of approximately 5 per 100,000 per year in the UK. It predominantly affects older adults — median age at diagnosis is 70 years — with a 2:1 male predominance. CLL and SLL represent the same disease: CLL is defined by ≥5×109/L circulating B lymphocytes with CLL immunophenotype; SLL by predominantly nodal disease with <5×109/L circulating CLL cells.
The disease course is highly variable — some patients live for decades without treatment, while others require early intervention and have rapidly progressive disease. This biological heterogeneity is now well-characterised by molecular markers (IGHV, TP53, del(17p)) and determines both prognosis and treatment selection.
Staging Systems
| Stage | Binet | Rai | Median Survival (historical — pre-targeted therapy era) |
|---|---|---|---|
| Early | A — <3 areas, Hb ≥10, plt ≥100 | 0 — lymphocytosis only | >10 years |
| Intermediate | B — ≥3 areas, Hb ≥10, plt ≥100 | I/II — adenopathy/splenomegaly | 5–7 years |
| Advanced | C — Hb <10 or plt <100 | III/IV — anaemia/thrombocytopenia | 2–4 years |
Methodology — Guideline Synthesis
This guideline integrates three international frameworks using GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. Each recommendation is tagged with its source society, evidence quality, and recommendation strength.
- ELN — via ESMO 2024 CLL guidance; European consensus
- BSH 2025 — UK national guideline; primary driver for UK practice
- ASH/NCCN 2024 — American guidance; educational context for UK
- iwCLL 2018 — Diagnostic and response criteria
- High — RCTs, meta-analyses with consistent results
- Moderate — RCTs with limitations or observational with strong effect
- Low — Observational or indirect evidence
- Very Low — Case series, expert opinion
Diagnosis and Initial Work-up
CLL is diagnosed by peripheral blood flow cytometry demonstrating a clonal B-cell population with characteristic immunophenotype. Bone marrow biopsy is not required for diagnosis but may be performed to assess marrow infiltration or to exclude concurrent haematological disorders.
Diagnostic Criteria (iwCLL 2018)
- Peripheral blood B-lymphocyte count ≥5×109/L persisting for ≥3 months
- Clonality confirmed by flow cytometry — co-expression of CD5, CD19, CD23 with weak surface immunoglobulin and either κ or λ light-chain restriction
- Characteristic CLL morphology on blood film — small mature lymphocytes with smear/smudge cells
- Matutes score ≥4 (CD5+, CD23+, CD79b weak/negative, FMC7 negative, sIg weak)
Distinguishing CLL from Monoclonal B-cell Lymphocytosis (MBL)
A frequently missed distinction in practice: if the clonal B-cell count is below 5×109/L with no lymphadenopathy, organomegaly, or cytopenias attributable to the clone, the diagnosis is Monoclonal B-cell Lymphocytosis (MBL), not CLL — even if the immunophenotype is identical. MBL progresses to CLL requiring treatment at approximately 1–2% per year. Clinical low-count MBL (clonal B cells <0.5×109/L) carries negligible transformation risk and warrants no haematology follow-up. High-count MBL (0.5–5×109/L) warrants 6–12 monthly monitoring. The distinction matters: MBL patients should not receive CLL-directed treatment.
Mandatory Initial Investigations
| Investigation | Purpose | Key Finding in CLL |
|---|---|---|
| FBC + blood film | Confirm lymphocytosis; exclude pseudo-lymphocytosis; smear cells | Lymphocytosis ≥5×109/L; smudge/smear cells characteristic of CLL but not specific enough to establish diagnosis without immunophenotyping |
| Flow cytometry | CLL immunophenotype (Matutes score) | CD5+/CD19+/CD23+; weak sIg; FMC7 negative |
| Immunoglobulins | Baseline; hypogammaglobulinaemia risk | Reduced IgG/IgA/IgM — increased infection risk |
| DAT (Direct Antiglobulin Test) | Baseline AIHA screen | Positive in ~7% at diagnosis |
| LDH, β2-microglobulin | Prognostic markers | Elevated correlates with advanced disease |
| Virology (HIV, HBV, HCV, CMV, EBV) | Mandatory before immunosuppression; reactivation risk | Screen all; HBV core Ab especially important before anti-CD20 |
Pre-Treatment Imaging
CT chest/abdomen/pelvis is not mandatory at diagnosis in asymptomatic CLL but is required before initiating treatment. It is used to assess lymphadenopathy burden, identify sites of bulky disease relevant to TLS risk stratification, evaluate splenomegaly, and provide a baseline for response assessment. In patients managed with watch and wait, repeat imaging is not routinely required unless clinical change suggests disease progression or Richter's transformation.
Prognostic Work-up and Molecular Markers
Molecular profiling is mandatory before initiating any line of treatment, but is not required at diagnosis in patients managed with watch and wait. Once a treatment decision is reached, a complete prognostic panel must be performed — including at each relapse, as molecular profiles can evolve. Results directly determine treatment selection, eligibility for targeted agents, and the risk-benefit ratio of each approach.
- FISH panel — del(17p), del(11q), trisomy 12, del(13q): hierarchical prognostic impact; del(17p) worst
- TP53 mutation sequencing — TP53 mutation = same prognostic and treatment implications as del(17p); must always test alongside FISH (FISH alone misses ~40% of TP53 aberrancy)
- IGHV mutation status — unmutated IGHV (<2% divergence from germline) = shorter PFS on all therapies; venetoclax benefits least when IGHV-unmutated
- Karyotype / FISH — complex karyotype (≥3 abnormalities) = inferior outcomes on all therapies including BTKi and venetoclax combinations; trial enrolment preferred
- CD38, ZAP-70 — surrogate markers; less actionable in the targeted therapy era but useful for overall risk stratification
• TP53 disruption (del(17p) and/or TP53 mutation): predicts poor or no response to DNA-damaging cytotoxic approaches; mandates the use of targeted therapy (BTKi or venetoclax-based), with agent selection guided by fitness, comorbidity, and patient factors.
• IGHV unmutated: predicts a more aggressive course and shorter remissions across most therapies; does not itself trigger treatment, but informs duration and depth of response expected with each approach.
• IGHV mutated: predicts deeper and more durable remissions — particularly with fixed-duration venetoclax combinations — and is therefore relevant to treatment selection, not timing.
Neither marker alone constitutes an indication to start treatment in an otherwise asymptomatic patient.
Prognostic Impact Summary
| Marker | Favourable | Unfavourable | Treatment Impact |
|---|---|---|---|
| TP53/del(17p) | Absent | Present | Avoid chemotherapy — must use BTKi or venetoclax-based; avoid ibrutinib+venetoclax TA891 data limited here |
| del(11q) | Absent | Present | Responds well to BTKi therapy; venetoclax combinations also effective |
| trisomy 12 | — | Intermediate | Good response to BTKi; associated with NOTCH1 mutation |
| del(13q) only | Present (sole abnormality) | — | Favourable — respond to all therapies |
| IGHV mutated | Mutated (≥2% divergence) | Unmutated (<2%) | Mutated IGHV: deeper and more durable responses; consider fixed-duration venetoclax strategy |
| Complex karyotype | Absent | ≥3 abnormalities | Inferior PFS on all therapies; prioritise novel agents; trial enrolment |
Treatment Indications — iwCLL Active Disease Criteria
The majority of newly diagnosed CLL patients do not require immediate treatment. Watch-and-wait is appropriate for asymptomatic patients regardless of lymphocyte count. Treatment is initiated only when active disease criteria are met.
- Progressive marrow failure: Worsening anaemia (Hb <10 g/dL) or thrombocytopenia (plt <100×109/L) due to CLL infiltration
- Massive or progressive splenomegaly: >6 cm below left costal margin, or symptomatic
- Massive or progressive lymphadenopathy: Longest diameter >10 cm, or symptomatic compression
- Progressive lymphocytosis: >50% increase over 2 months, or lymphocyte doubling time <6 months (if >30×109/L)
- Autoimmune cytopenias: AIHA or ITP poorly responding to corticosteroids
- Constitutional symptoms: Weight loss >10% in 6 months; extreme fatigue; fevers >38°C for ≥2 weeks without infection; night sweats >1 month without infection
- Asymptomatic Binet A or B
- Stable lymphocyte count (DT >12 months)
- No constitutional symptoms
- No progressive cytopenia
- Reassure: early treatment does NOT improve survival
- Lymphocyte count alone (>30, >100×109/L) without other criteria
- Positive prognostic markers alone (unmutated IGHV, del(17p) in asymptomatic patient)
- Patient or GP anxiety — education and reassurance preferred
- Hypogammaglobulinaemia — treat with Ig replacement, not CLL therapy
Fitness Assessment Before Treatment
All patients meeting treatment criteria should undergo formal fitness assessment before starting therapy. This determines treatment intensity and agent selection:
| Assessment Tool | Purpose | Threshold |
|---|---|---|
| CIRS (Cumulative Illness Rating Scale) | Comorbidity burden; determines fitness for intensive therapy | CIRS ≤6 with no single organ score >2 = fit for intensive regimens |
| eGFR / creatinine clearance | Renal function — affects venetoclax TLS risk; BTKi preferred if eGFR <30 | eGFR ≥70 mL/min generally supports use of all standard agents; eGFR <30 — BTKi preferred; venetoclax requires careful TLS risk assessment and monitoring |
| ECOG performance status | Functional capacity | ECOG 0–1 = fit; ECOG ≥2 consider reduced intensity or BTKi monotherapy |
| Cardiac assessment | Prior to BTKi — AF risk, anticoagulation status | Prior AF, anticoagulation = prefer acalabrutinib or zanubrutinib over ibrutinib |
First-Line Treatment
First-line treatment selection is guided by: (1) presence of del(17p) or TP53 mutation, (2) patient fitness (CIRS/eGFR/ECOG), and (3) patient preference (fixed-duration vs. continuous therapy). BSH 2025 endorses zanubrutinib and acalabrutinib as the preferred BTK inhibitors for new patients, with venetoclax-based fixed-duration combinations as the main alternative. Ibrutinib remains NICE-approved but is de-prioritised due to its inferior cardiac safety profile.
7a. TP53-Aberrant CLL — del(17p) and/or TP53 Mutation
In del(17p) and/or TP53-mutant CLL, only targeted agents (BTK inhibitors and venetoclax-based combinations) achieve meaningful responses. DNA-damaging cytotoxic regimens are not appropriate in this setting and should not be used.
7b. CLL Without TP53 Aberrancy — Treatment Selection
BSH 2025 (GRADE 1A): Zanubrutinib (TA931) and acalabrutinib (TA689) are the preferred BTK inhibitors for new patients, preferred over ibrutinib due to superior safety profiles. Venetoclax-based fixed-duration combinations are the main alternative. Selection is guided by:
- BTKi preference: Zanubrutinib 160 mg BD or acalabrutinib 100 mg BD — preferred for most new patients (lower AF, hypertension, bleeding vs ibrutinib)
- Fixed-duration option: Venetoclax + obinutuzumab (TA1119, 12 cycles) — preferred for patients wanting treatment-free remission; particularly effective in IGHV-mutated disease
- Cardiac risk / anticoagulation: Zanubrutinib or acalabrutinib preferred (lowest AF rates among BTKis); venetoclax-based also appropriate
- IGHV-mutated + fit: Consider venetoclax + obinutuzumab (TA1119) for deepest uMRD and treatment-free remission
- Renal impairment (eGFR <30): BTKi preferred — venetoclax requires careful TLS assessment and dose modification
- Ibrutinib (TA429/TA891): Remains NICE-approved but de-prioritised by BSH 2025 for new patients. Still appropriate if already established and tolerating well, or per Blueteq eligibility criteria.
Relapsed and Refractory CLL
Relapse or progression warrants urgent molecular re-evaluation — TP53 status can evolve (clonal evolution occurs in 20–30% at relapse) and the molecular profile at diagnosis should not be assumed at relapse. Choice of second-line therapy depends on prior treatment, mechanism of resistance, and fitness. For BTKi-refractory disease, venetoclax-based therapy is the preferred subsequent-line approach. For venetoclax-refractory disease, consider zanubrutinib if BTKi-naive, or pirtobrutinib if covalent BTKi-refractory (check current NICE TA).
- BTK C481S mutation — most common; prevents covalent binding of ibrutinib/acalabrutinib/zanubrutinib; pirtobrutinib active
- PLCγ2 mutations (PLCG2) — bypass BTK signalling; all BTKis may fail
- Clonal evolution — emergence of del(17p)/TP53 mutation at relapse (20–30% of cases); repeat FISH + TP53 sequencing mandatory
- Rapid doubling Richter's transformation — suspect if sudden weight loss, elevated LDH, rapidly enlarging single node — PET-CT and biopsy required
Response Assessment and MRD
| Response | Definition (iwCLL 2018) |
|---|---|
| Complete Response (CR) | No lymphadenopathy >1.5 cm, no splenomegaly, no B-symptoms, ALC <4×109/L, plt ≥100, Hb ≥11 (untreated by growth factors), BM normocellular without CLL nodules |
| Partial Response (PR) | ≥50% reduction in lymphadenopathy/organomegaly + improvement in cytopenias |
| Stable Disease (SD) | <50% reduction in measurable disease |
| Progressive Disease (PD) | ≥50% increase in measurable disease or new disease manifestation |
Note on MRD: MRD assessment is not a formal iwCLL response category (the 2018 iwCLL criteria define CR, PR, SD, PD based on clinical and haematological parameters). MRD status — assessed by flow cytometry or next-generation sequencing — is evaluated as an additional layer to guide treatment duration in fixed-duration regimens.
MRD Assessment
Undetectable MRD (uMRD4), defined as fewer than 1 CLL cell per 10,000 leucocytes (<10−4) by flow cytometry or next-generation sequencing, is an emerging surrogate endpoint used to guide treatment duration in fixed-duration regimens. uMRD at end of treatment in CLL14 correlated strongly with prolonged treatment-free remission.
Special Populations
10a. Richter's Transformation (RT)
Richter's transformation occurs in 2–10% of CLL patients at an annual incidence of 0.5–1%. In ~90% of cases the histology is DLBCL (clonally related in ~80%); the remainder are Hodgkin lymphoma. Median OS post-RT is approximately 9 months with conventional therapy — overall prognosis is poor.
- Sudden deterioration with new or rapidly growing lymph node (often asymmetric)
- Markedly elevated LDH (disproportionate to lymphocyte count)
- B-symptoms emerging or worsening without intercurrent infection
- PET-CT: highly avid FDG uptake in single or asymmetric nodal group (SUVmax >5)
Action: PET-CT + biopsy of most metabolically active node. Do NOT rebiopsy the same site if initial biopsy was non-diagnostic — biopsy the most active PET site.
- Enrol on clinical trial where possible — no standard of care
- R-CHOP if no trial available — inferior outcomes compared with de novo DLBCL
- CAR-T (CD19-directed) — ORR 60–65%; responses can be durable
- Bispecific antibodies (epcoritamab, mosunetuzumab) — promising in R/R RT; check TA status
- ASCT consolidation for chemosensitive RT in eligible patients
- Palliative intent if poor PS or major comorbidity
- Autoimmune cytopenias (AIHA, ITP) occur in up to 20% of CLL patients during their illness course (BSH 2012: 10–20%; AIHA specifically ~7%; DAT positive without haemolysis in a further 7–14%)
- Diagnose AIHA: DAT positive + haemolysis (elevated LDH, bilirubin, reticulocyte count)
- First-line: Manage as for primary autoimmune cytopenia — corticosteroids (prednisolone 1 mg/kg, tapering over 2–4 weeks) are the usual initial treatment
- CLL-directed therapy is indicated when: the autoimmune complication is refractory to steroids, recurrent, steroid-dependent, or occurs in the context of active/progressive CLL requiring treatment in its own right
- If steroids fail or CLL therapy not yet due: rituximab 375 mg/m2 ×4
- Avoid fludarabine-containing regimens in active AIHA — can worsen haemolysis
- Evans syndrome (AIHA + ITP): higher complexity — specialist input
10b. CLL in Pregnancy
- Observation: Most CLL in pregnancy does not require CLL-directed treatment — indolent course permits deferral until postpartum in most cases
- Symptomatic hypogammaglobulinaemia: IVIG safe in pregnancy; subcutaneous Ig alternative
- If treatment required: Multidisciplinary approach (haematology + obstetrics + neonatology); consider timing (avoid 1st trimester if possible)
- Avoid BTK inhibitors: Limited safety data; teratogenicity potential in animal studies — risk/benefit discussion required
- Avoid venetoclax: No adequate human pregnancy data; embryotoxic in animal models
- If urgent treatment needed: Anti-CD20 ± corticosteroids or single-agent rituximab (neonatal B-cell depletion reported — notify neonatology)
- Neonatal monitoring: Check cord blood for thrombocytopenia; neonatal B-cell monitoring if maternal anti-CD20 received
10c. Hypogammaglobulinaemia and Infection Prophylaxis
- Immunoglobulin replacement (IgRT): IVIG or SCIG when IgG <4 g/L with recurrent bacterial infections (≥2 significant infections per year) — not for IgG low without clinical infection
- Pneumocystis jirovecii prophylaxis: Co-trimoxazole 480 mg BD (3 days/week) during and for 6–12 months after purine analogue, venetoclax, or anti-CD20 therapy
- Herpes simplex/zoster prophylaxis: Aciclovir 400 mg BD (or valaciclovir 500 mg BD) during and for ≥6 months after venetoclax-based combinations or intensive anti-CD20 therapy; consult local protocol — BSH guidance does not mandate it for BTKi monotherapy but it is commonly prescribed
- CMV monitoring: Routine weekly CMV PCR is an alemtuzumab-era protocol — alemtuzumab is no longer used in CLL in the UK. Targeted therapies (BTKis, venetoclax) carry significantly lower CMV reactivation risk. CMV monitoring is not routinely required for patients on BTKi monotherapy or venetoclax. Consider CMV surveillance in: (1) venetoclax + anti-CD20 combinations in significantly immunocompromised patients with known CMV seropositivity; (2) post-allogeneic SCT (a small minority of CLL patients); (3) patients with severe combined immunodeficiency or unexplained cytopenias on treatment. Follow local haematology/virology protocols.
- Vaccinations: Annual influenza (inactivated); pneumococcal (PCV13 + PPSV23); COVID-19; hepatitis B; shingles vaccine (Shingrix — recombinant; live vaccines contraindicated)
- HBV reactivation: Screen all patients — HBV core Ab positive patients require prophylactic antiviral (entecavir or tenofovir) during anti-CD20 treatment
Audit Standards
The following quality indicators can be used to audit CLL management practice against BSH 2025 and NICE commissioning requirements.
| Audit Standard | Data Source | Target | Rationale |
|---|---|---|---|
| Flow cytometry performed and documented in all newly diagnosed CLL cases | Haematology database, clinic letters | ≥98% | iwCLL diagnostic requirement |
| TP53 sequencing AND FISH for del(17p) performed before each line of treatment | Molecular lab records, clinic letters | ≥95% | BSH 2025 — TP53 alone insufficient |
| IGHV mutation status documented before first treatment | Molecular lab records | ≥90% | Informs treatment strategy per BSH |
| Chemoimmunotherapy NOT used as first-line treatment unless documented rationale | Prescribing records, MDT notes | ≥95% | BSH 2025: targeted agents are standard of care |
| NICE TA used for first-line treatment (TA931, TA689, TA1119, or TA891) | Blueteq / pharmacy records | ≥95% | Blueteq/commissioning compliance — zanubrutinib (TA931) and acalabrutinib (TA689) preferred for new starts per BSH 2025 |
| HBV status checked before anti-CD20 therapy; prophylaxis prescribed if HBcAb+ | Virology, prescribing | 100% | Fatal HBV reactivation risk |
| iwCLL active disease criteria documented as reason for treatment initiation | Clinic letters, MDT records | ≥95% | Avoids premature treatment |
Limitations and Update Plan
- Zanubrutinib (TA931) and acalabrutinib (TA689) are both NICE-commissioned for first-line CLL; Blueteq eligibility criteria should be verified for individual patients before prescribing.
- Head-to-head comparison between acalabrutinib and venetoclax+obinutuzumab in first-line is not yet available from phase III data — selection continues to be based on indirect comparisons and patient/clinician preference.
- MRD-guided treatment duration is an active research question — not yet part of routine UK clinical practice outside trials.
- Ibrutinib+venetoclax (TA891) data in del(17p)/TP53-mutant CLL are more limited — BSH guidance favours alternative approaches in this group until further data.
- Pirtobrutinib is EMA-approved for R/R CLL post-covalent BTKi; NICE appraisal status should be verified before prescribing.
- SLL (Small Lymphocytic Lymphoma) shares the same biological entity and treatment principles as CLL; high-level recommendations apply to both. Detailed SLL-specific diagnostic nuances (particularly regarding nodal biopsy, PET-CT staging, and tissue diagnosis) are not addressed here — haematology lymphoma MDT review is recommended for SLL-dominant presentations. Waldenström macroglobulinaemia is a distinct entity not covered by this guideline.
Update schedule: This guideline will be reviewed in April 2027 or earlier following updated BSH CLL guidance, new NICE technology appraisals, or major changes to ELN/ASH recommendations.
References
References graded by credibility: A1 Society guideline A2 High-quality RCT/meta-analysis B Observational/secondary source
- Follows CE et al. BSH guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2025;207(6):2296–2313. [PMID: 41069109] [DOI:10.1111/bjh.70100] A1
- ESMO Clinical Practice Guideline update on new targeted therapies in CLL (first-line and relapse). Annals of Oncology, 2024. A1
- NCCN Clinical Practice Guidelines in Oncology: CLL/SLL, Version 2.2024. A1
- Sharman JP et al. ELEVATE-TN: acalabrutinib ± obinutuzumab vs chlorambucil-obinutuzumab, treatment-naive CLL. Lancet. 2020;395(10232):1278–1291. 6-year update (74.5 months): EHA 2024 A2
- Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated CLL: 6-year CLL14 results. Blood. 2024;144(18):1924–1935. [PMID: 39082668] [DOI:10.1182/blood.2024024631] A2
- Barr PM et al. Up to 8-year follow-up from RESONATE-2: ibrutinib in treatment-naive CLL. Blood Advances. 2022. [10-year congress data presented 2025; PMID pending indexing] A2
- Brown JR et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory CLL (ALPINE). N Engl J Med. 2023;388(4):319–332. [PMID: 36511784] A2
- Kater AP et al. MURANO final analysis: venetoclax-rituximab 7-year OS. Blood. 2025;145(23):2733–2745. [PMID: 40009494] A2
- Eichhorst B et al. GAIA/CLL13 primary analysis. Lancet. 2023;401(10386):1353–1365. [uMRD 86.5% at month 15 confirmed] | 4-year update: Fürstenau M et al. Lancet Oncol. 2024;25(6):744–759. [PMID: 38821083] A2
- Jurczak W et al. ASCEND final analysis: acalabrutinib vs IdR/BR. Haematologica. 2022. A2
- Tam CS et al. SEQUOIA arm C 5-year follow-up: zanubrutinib in del(17p)/treatment-naive CLL. EHA 2025 abstract. Hematological Oncology. 2025;43(S3). [DOI:10.1002/hon.70093_72] A2
- NICE TA429 — ibrutinib for previously treated CLL and for untreated CLL with del(17p)/TP53 mutation where chemoimmunotherapy is unsuitable. NICE, 2017. A1
- NICE TA1119 — venetoclax + obinutuzumab for untreated CLL (updates and replaces TA663). NICE, January 2026. A1
- NICE TA931 — zanubrutinib for untreated CLL. NICE, 2024. A1
- NICE TA689 — acalabrutinib for previously untreated and previously treated CLL. NICE, 2021. A1
- NICE TA891 — ibrutinib + venetoclax for untreated CLL. NICE, 2023. A1
- NICE TA561 — venetoclax + rituximab for R/R CLL. NICE, 2019. & TA796 — venetoclax monotherapy for R/R CLL. NICE, 2022. A1